Inovio Pharmaceuticals (INO) Presents Positive dBiTE Data At AACR - Maxim

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Inovio Pharmaceuticals (INO) Presents Positive dBiTE Data At AACR - Maxim

Inovio Pharma (INO) Reports HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study

April 3, 2019 9:03 AM EDT

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent respiratory papillomatosis (RRP). RRP is an HPV-associated disease that can cause noncancerous tumor growths leading to life-threatening airway obstructions, and occasionally progresses to cancer. RRP is primarily caused by two strains of HPV, HPV 6 and 11, which also predominantly cause genital warts. RRP may occur in adults (adult-onset RRP) as well as in children (juvenile-onset RRP) who are thought to have contracted the virus during childbirth.... More